Live Analyst Rating Changes 24957 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Lachlan Hanbury Brown
WB

Lachlan Hanbury Brown

William Blair
Wall Street Analyst
★★☆☆☆
#2678
on 13Foresight · ranked by our own returns
44%
Success Rate
-4.8%
Average Return
15 of 34 calls profitable · -7.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 44% of Lachlan Hanbury Brown's ratings turned a profit when each position was held for 1 year — averaging -4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

109 Buy 5 Hold 0 Sell
Lachlan's Stock Coverage 11 ratings · 2026-08-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SPRY
ARS Pharmaceuticals
 Aug 14, 2026 BUY Strong Buy
+275.7% avg upside
12 analysts
 — +0.0% ·
LENZ
LENZ Therapeutics
 Aug 12, 2026 BUY Buy
+336.8% avg upside
17 analysts
 — -6.2% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 12, 2026 BUY Strong Buy
+141.9% avg upside
9 analysts
 — +2.4% ·
TARS
Tarsus Pharmaceuticals
 Aug 12, 2026 BUY Strong Buy
+11.9% avg upside
16 analysts
 — -1.2% ·
KLRS
Kalaris Therapeutics
 Aug 11, 2026 BUY Buy
+214.4% avg upside
13 analysts
 — +3.5% ·
HROW
Harrow Health
 Aug 10, 2026 BUY Strong Buy
+36.4% avg upside
12 analysts
 — -1.7% ·
VRDN
Viridian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+59.5% avg upside
32 analysts
 — -1.9% ·
OCUL
Ocular Therapeutix
 Aug 03, 2026 BUY Strong Buy
+146.2% avg upside
21 analysts
 — +19.5% ·
LYRA
Lyra Therapeutics
 Jun 09, 2026 HOLD Hold
+9100.0% avg upside
7 analysts
 — -68.8% ·
SLDB
Solid Biosciences
 Mar 20, 2026 BUY Strong Buy
+72.9% avg upside
23 analysts
 — +30.9% ·
ZVRA
Zevra Therapeutics
 Mar 16, 2026 BUY Strong Buy
+94.8% avg upside
15 analysts
 — +14.7% ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Lachlan Hanbury Brown — Frequently Asked Questions
How accurate are Lachlan Hanbury Brown's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Lachlan's ratings were profitable over a one-year hold, with an average return of -4.8% per rating, or -7.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Lachlan ranked on 13Foresight?
Lachlan Hanbury Brown is currently ranked #2678 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Lachlan cover?
Lachlan most recently has ratings on SPRY, LENZ, TSE:EPRX, TARS, KLRS, HROW, VRDN, OCUL, LYRA, SLDB, ZVRA. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.